En liten oppsummering så langt:

Dlbcl: Nordic Nanovector: Safety Review Committee Approves Advancing to Final Dosing Regimen in Phase 1 Trial of Betalutin® in DLBCL
Oslo, Norway, 10 April 2019
Dvs dlbcl går som.planlagt

Archer:

21/05-2019 11:44:18: (NANO) Nordic Nanovector: Archer-1 phase 1b Betalutin®/rituximab combination trial advances to next cohort
Nordic Nanovector ASA (OSE: NANO) announces that following a safety review of the first patients in the ongoing Archer-1 (LYMRIT 37-07) trial investigating
Betalutin® (177Lu-satetraxetan-lilotomab) in combination with rituximab (RTX) in second-line follicular lymphoma (2L FL), the Betalutin® dose has been escalated
to 15 MBq/kg for the next cohort of

Leukemias:
Nordic Nanovector: Promising results from preclinical studies with a novel CD37-targeted alpha therapy for B-cell tumours presented at TAT11 (leukemias)
Ser lovende ut.

Til slutt paradigme:

We are delighted by the MHRA’s decision to award PIM designation to Betalutin®. This acknowledges the high unmet medical need of this patient population as well as the potential of Betalutin® to offer therapeutic benefits to FL patients. Both the PIM and Fast Track designations (granted by the FDA in June) are very encouraging, as they provide opportunities for enhanced dialogue with health authorities and the potential to bring Betalutin® to patients more quickly.”
potential
Totalt sett ser det ut som faktisk alt går etter planen. At de kan bli ledende selskap innen blodkreft er faktisk mulig